FDA sets June de­ci­sion dead­line for po­ten­tial full ap­proval, la­bel ex­pan­sion of Sarep­ta’s Duchenne gene ther­a­py

Sarep­ta Ther­a­peu­tics could soon notch an­oth­er reg­u­la­to­ry win.

De­spite the com­pa­ny and its Duchenne gene ther­a­py get­ting dogged by de­bate, and then a failed con­fir­ma­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER